Belgium's UCB in autoimmune drug deal with Antengene
Published on March 4, 2026.
Belgian drugmaker UCB has agreed to license Antengene's experimental autoimmune disease therapy, ATG-201, for $60 million up front and potentially $1.1 billion more if certain milestones are met. The deal highlights the unique capabilities of Antegene's development platform. The agreement covers the development, manufacturing, and commercialization of ATg-201 and access to associated manufacturing technology.
Related Articles
German union aims for breakthrough at Tesla Berlin plant
The IG Metall union is campaigning for a works council majority at Tesla's Berlin plant, amid internal conflicts and legal challenges.
North America’s largest construction trade show returns to Las Vegas — PHOTOS
ConExpo-Con/Agg 2026 returns to Las Vegas, featuring exhibits including cranes and lifting equipment, John Deere 145 P-Tier excavator, and a variety of other notable products.
Benson Targets Private Equity in Michigan Housing Plan - WOWO News/Talk 92.3 FM and 1190 AM
Jocelyn Benson proposes tax credits, regulatory reforms, and a temporary ban on short-term rentals to address Michigan's housing shortage.